Research aimed at improving neonatal and pediatric outcomes highlighted both biomarker discovery and clinical tool evaluation. One study in Pediatric Research compared early-onset sepsis approaches, assessing performance of the early-onset sepsis risk calculator and American Academy of Pediatrics guidelines to determine where predictions may diverge in practice. A separate sepsis-related mechanism study described mesenchymal stem cell-derived small extracellular vesicles delivering miR-125a-5p to suppress pyroptosis in sepsis-induced acute kidney injury. The report frames the vesicle cargo as a pathway-level intervention candidate to reduce inflammatory programmed cell death. For post-hemorrhagic ventricular dilation, cerebral NIRS was presented as a potential management input in severe neonatal brain injury, while other neonatal work continued to explore ICU mortality biomarkers. These developments reinforce a common biotech priority in critical care: moving from broad risk rules to measurable, mechanism-anchored signals that can be operationalized quickly in the NICU and pediatric settings.